ARTICLE | Finance
Follow your heart
Third Rock backs MyoKardia genetic approach to personalized heart failure drugs
September 24, 2012 7:00 AM UTC
Third Rock provided newco MyoKardia Inc. with $38 million in series A money in hopes the biotech will parlay its founders' scientific insights about myosin, a key component of muscle contraction, into small molecules to treat genetic forms of heart disease.
"There are 5 million people in the U.S. with heart failure, but no genetic basis for understanding who is at risk," said Third Rock's Charles Homcy, who is interim CEO of MyoKardia...